Tag: contralateralBreastCancer

Articles

• BRCA1 and BRCA2 mutation carriers
• Breast cancer in old age
• Inflammatory breast cancer characteristics
• Lobular breast cancer and LCIS characteristics
• Lobular breast cancer prognosis
• Patterns of recurrence in triple negative breast cancer patients

News

11/18/17

Late recurrence of ER+ BC linked to primary tumor characteristics

06/02/15

Local recurrence rates for LCIS can be significant

01/05/13

Those with family history at higher risk of BC in other breast

09/04/12

Contralateral breast cancer has worse prognosis than initial primary

04/18/12

Breast cancer survivors at higher risk of new breast tumors

12/11/10

Radiotherapy substantially reduces additional BC in women with DCIS

11/04/10

MRIs find additional disease in 20% of lobular BC patients

10/18/10

Women with DCIS and dense breasts have a higher risk of additional BC

Studies

• Breast Cancer in the Tissue of the Contralateral Breast Reduction Cite
  Kuijlaars ZM, Hillberg NS, Kooreman L, Severens–Rijvers CA, Qiu SS. Breast Cancer in the Tissue of the Contralateral Breast Reduction. MDPI AG; 2023; 10.20944/preprints202312.0014.v1
• Risk of contralateral breast cancer among Asian/Pacific Islander women in the United States Cite
  Huang H, Guadamuz JS, Hoskins KF, Ko NY, Calip GS. Risk of contralateral breast cancer among Asian/Pacific Islander women in the United States. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07140-6
• Contralateral breast cancer risk with radiation therapy in BRCA mutation carriers: what do we tell patients? Cite
  Lee MK, Robson ME. Contralateral breast cancer risk with radiation therapy in BRCA mutation carriers: what do we tell patients?. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2023; 10.1093/jnci/djad129
• Survival After Contralateral Secondary Breast Cancer by Age Group in California Cite
  Perry LM, Keegan THM, Li Q, Bold RJ, Antonino NF, Maguire FB, et al. Survival After Contralateral Secondary Breast Cancer by Age Group in California. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 10.1245/s10434-023-13902-9
• Risk of second primary cancer among women in the Kaiser Permanente Breast Cancer Survivors Cohort Cite
  Ramin C, Veiga LHS, Vo JB, Curtis RE, Bodelon C, Aiello Bowles EJ, et al. Risk of second primary cancer among women in the Kaiser Permanente Breast Cancer Survivors Cohort. Breast Cancer Research. Springer Science and Business Media LLC; 2023; 25 10.1186/s13058-023-01647-y
• Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy Cite
  Nordenskjöld A, Fohlin H, Rosell J, Bengtsson N, Fornander T, Hatschek T, et al. Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy. Research Square Platform LLC; 2023; 10.21203/rs.3.rs-2856174/v1
• Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers Cite
  Nemati Shafaee M, Goutsouliak K, Lin H, Bevers TB, Gutierrez-Barrera A, Bondy M, et al. Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06688-z
• Risk of contralateral breast and other cancers in patients with invasive lobular breast cancer. Cite
  Choong GMY, Savitz ST, Giridhar K, Haddad TC, Ruddy KJ, Boughey JC, et al. Risk of contralateral breast and other cancers in patients with invasive lobular breast cancer.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022; 40:555-555 10.1200/jco.2022.40.16_suppl.555
• Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients Cite
  Lin P, Chen S, Tseng L, Chang K, Huang A, Cheng K, et al. Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-021-06446-7
• Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography Cite
  Altoe ML, Kalinsky K, Marone A, Kim HK, Guo H, Hibshoosh H, et al. Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography. Breast Cancer Research. Springer Science and Business Media LLC; 2021; 23 10.1186/s13058-021-01396-w
• Risk factors for contralateral breast cancer in postmenopausal breast cancer survivors in the NIH-AARP Diet and Health Study Cite
  Ramin C, Mullooly M, Schonfeld SJ, Advani PG, Bodelon C, Gierach GL, et al. Risk factors for contralateral breast cancer in postmenopausal breast cancer survivors in the NIH-AARP Diet and Health Study. Cancer Causes & Control. Springer Science and Business Media LLC; 2021; 10.1007/s10552-021-01432-2
• Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer Cite
  Giardiello D, Kramer I, Hooning MJ, Hauptmann M, Lips EH, Sawyer E, et al. Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer. npj Breast Cancer. Springer Science and Business Media LLC; 2020; 6 10.1038/s41523-020-00202-8
• Association Use of Bisphosphonates with Risk of Breast Cancer: A Meta-Analysis Cite
  Peng R, Liang X, Zhang G, Yao Y, Chen Z, Pan X, et al. Association Use of Bisphosphonates with Risk of Breast Cancer: A Meta-Analysis. BioMed Research International. Hindawi Limited; 2020; 2020:1-13 10.1155/2020/5606573
• Bilateral Disease Common Among Slovenian CHEK2-Positive Breast Cancer Patients Cite
  Nizic-Kos T, Krajc M, Blatnik A, Stegel V, Skerl P, Novakovic S, et al. Bilateral Disease Common Among Slovenian CHEK2-Positive Breast Cancer Patients. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2020; 10.1245/s10434-020-09178-y
• Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients Cite
  Su L, Xu Y, Ouyang T, Li J, Wang T, Fan Z, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients. International Journal of Cancer. Wiley; 2020; 146:3335-3342 10.1002/ijc.32918
• Magnitude of reduction in risk of second contralateral breast cancer with bilateral mastectomy in patients with breast cancer: Data from California, 1998 through 2015 Cite
  Kurian AW, Canchola AJ, Ma CS, Clarke CA, Gomez SL. Magnitude of reduction in risk of second contralateral breast cancer with bilateral mastectomy in patients with breast cancer: Data from California, 1998 through 2015. Cancer. Wiley; 2019; 126:958-970 10.1002/cncr.32618
• Effects of adjuvant tamoxifen over three decades on breast cancer–free and distant recurrence–free interval among premenopausal women with oestrogen receptor–positive breast cancer randomised in the Swedish SBII:2pre trial Cite
  Ekholm M, Bendahl P, Fernö M, Nordenskjöld B, Stål O, Rydén L. Effects of adjuvant tamoxifen over three decades on breast cancer–free and distant recurrence–free interval among premenopausal women with oestrogen receptor–positive breast cancer randomised in the Swedish SBII:2pre trial. European Journal of Cancer. Elsevier BV; 2019; 110:53-61 10.1016/j.ejca.2018.12.034
• Statin use and risk of contralateral breast cancer: a nationwide cohort study Cite
  Langballe R, Cronin-Fenton D, Dehlendorff C, Jensen M, Ejlertsen B, Andersson M, et al. Statin use and risk of contralateral breast cancer: a nationwide cohort study. British Journal of Cancer. Springer Science and Business Media LLC; 2018; 119:1297-1305 10.1038/s41416-018-0252-1
• Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women Cite
  Yoon TI, Kwak BS, Yi OV, Kim S, Um E, Yun KW, et al. Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 173:657-665 10.1007/s10549-018-5031-4
• Low-dose aspirin use and risk of contralateral breast cancer: a Danish nationwide cohort study Cite
  Bens A, Friis S, Dehlendorff C, Jensen M, Ejlertsen B, Kroman N, et al. Low-dose aspirin use and risk of contralateral breast cancer: a Danish nationwide cohort study. Preventive Medicine. Elsevier BV; 2018; 116:186-193 10.1016/j.ypmed.2018.09.015
• Estrogen-receptor status and risk of contralateral breast cancer following DCIS Cite
  Stout NK, Cronin AM, Uno H, Ozanne EM, Hassett MJ, Frank ES, et al. Estrogen-receptor status and risk of contralateral breast cancer following DCIS. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 171:777-781 10.1007/s10549-018-4860-5
• Phase II national clinical trial of prophylactic irradiation to the contralateral breast for BRCA mutation carriers treated for early breast cancer (EBC). Cite
  Evron E, Ben David MA, Goldberg H, Fried G, Kaufman B, Catane R, et al. Phase II national clinical trial of prophylactic irradiation to the contralateral breast for BRCA mutation carriers treated for early breast cancer (EBC).. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018; 36:514-514 10.1200/jco.2018.36.15_suppl.514
• Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women’s Environmental Cancer and Radiation Epidemiology Study Cite
  Reiner AS, Sisti J, John EM, Lynch CF, Brooks JD, Mellemkjær L, et al. Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women’s Environmental Cancer and Radiation Epidemiology Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018; 36:1513-1520 10.1200/jco.2017.77.3424
• Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women’s Environmental Cancer and Radiation Epidemiology Study Cite
  Reiner AS, Sisti J, John EM, Lynch CF, Brooks JD, Mellemkjær L, et al. Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women’s Environmental Cancer and Radiation Epidemiology Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018; 36:1513-1520 10.1200/jco.2017.77.3424
• Incidence and tumour characteristics of bilateral and unilateral interval breast cancers at screening mammography Cite
  van Bommel RM, Voogd AC, Nederend J, Setz-Pels W, Louwman MW, Strobbe LJ, et al. Incidence and tumour characteristics of bilateral and unilateral interval breast cancers at screening mammography. The Breast. Elsevier BV; 2018; 38:101-106 10.1016/j.breast.2017.12.018
• Higher risk of metachronous contralateral breast cancer in patients with invasive lobular breast cancer Cite
  Akdeniz D, Kramer I, Van Deurzen C, Schaapveld M, Westenend P, Voogd A, et al. Higher risk of metachronous contralateral breast cancer in patients with invasive lobular breast cancer. European Journal of Cancer. Elsevier BV; 2018; 92:S46 10.1016/s0959-8049(18)30364-2
• Comparison of failure patterns between tubular breast carcinoma and invasive ductal carcinoma (KROG 14–25) Cite
  Cho WK, Choi DH, Lee J, Park W, Kim YB, Suh C, et al. Comparison of failure patterns between tubular breast carcinoma and invasive ductal carcinoma (KROG 14–25). The Breast. Elsevier BV; 2018; 38:165-170 10.1016/j.breast.2018.01.004
• 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years Cite
  Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. New England Journal of Medicine. Massachusetts Medical Society; 2017; 377:1836-1846 10.1056/nejmoa1701830
• Bisphosphonate use and the risk of breast cancer: a meta-analysis of observational studies Cite
  Ou Y, Chiu H, Wong Y, Yang C, Yang Y. Bisphosphonate use and the risk of breast cancer: a meta-analysis of observational studies. Pharmacoepidemiology and Drug Safety. Wiley; 2017; 26:1286-1295 10.1002/pds.4302
• Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy? Cite
  Miller ME, Muhsen S, Olcese C, Patil S, Morrow M, Van Zee KJ. Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy?. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2017; 24:2889-2897 10.1245/s10434-017-5931-2
• Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population Cite
  Reiner AS, Lynch CF, Sisti JS, John EM, Brooks JD, Bernstein L, et al. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population. Breast Cancer Research. Springer Science and Business Media LLC; 2017; 19 10.1186/s13058-017-0874-x
• Alcohol consumption and cigarette smoking in combination: A predictor of contralateral breast cancer risk in the WECARE study Cite
  Knight JA, Fan J, Malone KE, John EM, Lynch CF, Langballe R, et al. Alcohol consumption and cigarette smoking in combination: A predictor of contralateral breast cancer risk in the WECARE study. International Journal of Cancer. Wiley; 2017; 141:916-924 10.1002/ijc.30791
• Abstract P2-07-05: Risk of metachronous contralateral breast cancer: Systematic review and meta-analysis Cite
  Akdeniz D, Schmidt M, McCool D, van den Broek A, Hauptmann M, Seynaeve C, et al. Abstract P2-07-05: Risk of metachronous contralateral breast cancer: Systematic review and meta-analysis. Poster Session Abstracts. American Association for Cancer Research; 2017; 10.1158/1538-7445.sabcs16-p2-07-05
• Mammographic breast density is associated with the development of contralateral breast cancer Cite
  Raghavendra A, Sinha AK, Le-Petross HT, Garg N, Hsu L, Patangan M, et al. Mammographic breast density is associated with the development of contralateral breast cancer. Cancer. Wiley; 2017; 123:1935-1940 10.1002/cncr.30573
• Risks of second malignancies after breast cancer treatment: Long-term results Cite
  Bazire L, De Rycke Y, Asselain B, Fourquet A, Kirova Y. Risks of second malignancies after breast cancer treatment: Long-term results. Cancer/Radiothérapie. Elsevier BV; 2017; 21:10-15 10.1016/j.canrad.2016.07.101
• The impact of in situ breast cancer and family history on risk of subsequent breast cancer events and mortality - a population-based study from Sweden Cite
  Sackey H, Hui M, Czene K, Verkooijen H, Edgren G, Frisell J, et al. The impact of in situ breast cancer and family history on risk of subsequent breast cancer events and mortality - a population-based study from Sweden. Breast Cancer Research. Springer Science and Business Media LLC; 2016; 18 10.1186/s13058-016-0764-7
• Early onset breast cancer in Ashkenazi women carriers of founderBRCA1/2mutations: beyond 10 years of follow-up Cite
  Dagan E, Gershoni-Baruch R, Kurolap A, Fried G. Early onset breast cancer in Ashkenazi women carriers of founderBRCA1/2mutations: beyond 10 years of follow-up. European Journal of Cancer Care. Wiley; 2016; 26:e12594 10.1111/ecc.12594
• Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting Cite
  Gierach GL, Curtis RE, Pfeiffer RM, Mullooly M, Ntowe EA, Hoover RN, et al. Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting. JAMA Oncology. American Medical Association (AMA); 2017; 3:186 10.1001/jamaoncol.2016.3340
• Reproductive factors, tumor estrogen receptor status and contralateral breast cancer risk: results from the WECARE study Cite
  Sisti JS, Bernstein JL, Lynch CF, Reiner AS, Mellemkjaer L, Brooks JD, et al. Reproductive factors, tumor estrogen receptor status and contralateral breast cancer risk: results from the WECARE study. SpringerPlus. Springer Science and Business Media LLC; 2015; 4 10.1186/s40064-015-1642-y
• Cytologic atypia in the contralateral unaffected breast is related to parity and estrogen-related genes Cite
  Monahan DA, Wang J, Lee O, Revesz E, Taft N, Ivancic D, et al. Cytologic atypia in the contralateral unaffected breast is related to parity and estrogen-related genes. Surgical Oncology. Elsevier BV; 2016; 25:449-456 10.1016/j.suronc.2015.12.001
• Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases Cite
  Cutuli B, De Lafontan B, Kirova Y, Auvray H, Tallet A, Avigdor S, et al. Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases. Radiation Oncology. Springer Science and Business Media LLC; 2015; 10 10.1186/s13014-015-0379-7
• Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status Cite
  Nilsson MP, Hartman L, Idvall I, Kristoffersson U, Johannsson OT, Loman N. Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2014; 144:133-142 10.1007/s10549-014-2842-9
• Potential Reduction of Contralateral Second Breast-Cancer Risks by Prophylactic Mammary Irradiation: Validation in a Breast-Cancer-Prone Mouse Model Cite
  Shuryak I, Smilenov LB, Kleiman NJ, Brenner DJ. Potential Reduction of Contralateral Second Breast-Cancer Risks by Prophylactic Mammary Irradiation: Validation in a Breast-Cancer-Prone Mouse Model. PLoS ONE. Public Library of Science (PLoS); 2013; 8:e85795 10.1371/journal.pone.0085795
• Effectiveness of routine follow-up in the detection of contralateral breast cancer in young women with early breast cancer Cite
  Koedijk M, van der Sangen M, Poortmans P, van Mierlo-Jansen P, van den Broek W, Storck B, et al. Effectiveness of routine follow-up in the detection of contralateral breast cancer in young women with early breast cancer. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2013; 39:1186-1191 10.1016/j.ejso.2013.08.031
• A population perspective to mitigating risk for second primary breast cancer Cite
  Lowery JT, Risendal BC. A population perspective to mitigating risk for second primary breast cancer. Breast Cancer Management. Future Medicine Ltd; 2013; 2:123-134 10.2217/bmt.13.6
• Risk of Asynchronous Contralateral Breast Cancer in Noncarriers of BRCA1 and BRCA2 Mutations With a Family History of Breast Cancer: A Report From the Women's Environmental Cancer and Radiation Epidemiology Study Cite
  Reiner AS, John EM, Brooks JD, Lynch CF, Bernstein L, Mellemkjær L, et al. Risk of Asynchronous Contralateral Breast Cancer in Noncarriers of BRCA1 and BRCA2 Mutations With a Family History of Breast Cancer: A Report From the Women's Environmental Cancer and Radiation Epidemiology Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2013; 31:433-439 10.1200/jco.2012.43.2013
• Estrogen Receptor Status in Relation to Risk of Contralateral Breast Cancer–A Population-Based Cohort Study Cite
  Sandberg MEC, Hall P, Hartman M, Johansson ALV, Eloranta S, Ploner A, et al. Estrogen Receptor Status in Relation to Risk of Contralateral Breast Cancer–A Population-Based Cohort Study. PLoS ONE. Public Library of Science (PLoS); 2012; 7:e46535 10.1371/journal.pone.0046535
• Tumor Stage Affects Risk and Prognosis of Contralateral Breast Cancer: Results From a Large Swedish-Population–Based Study Cite
  Vichapat V, Garmo H, Holmqvist M, Liljegren G, Wärnberg F, Lambe M, et al. Tumor Stage Affects Risk and Prognosis of Contralateral Breast Cancer: Results From a Large Swedish-Population–Based Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:3478-3485 10.1200/jco.2011.39.3645
• Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer Cite
  Saltzman BS, Malone KE, McDougall JA, Daling JR, Li CI. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 135:849-855 10.1007/s10549-012-2183-5
• Invasive lobular (ILC) versus invasive ductal (IDC) breast cancer (BC): Clinical-pathologic features and clinical outcomes in monoinstitutional series. Cite
  Ferro A, Eccher C, Caldara A, Triolo R, Barbareschi M, Cuorvo LV, et al. Invasive lobular (ILC) versus invasive ductal (IDC) breast cancer (BC): Clinical-pathologic features and clinical outcomes in monoinstitutional series.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:e21102-e21102 10.1200/jco.2012.30.15_suppl.e21102
• Second malignancies after breast cancer: the impact of different treatment modalities Cite
  Kirova YM, De Rycke Y, Gambotti L, Pierga J, Asselain B, Fourquet A. Second malignancies after breast cancer: the impact of different treatment modalities. British Journal of Cancer. Springer Science and Business Media LLC; 2008; 98:870-874 10.1038/sj.bjc.6604241
• Risk of Primary Non–Breast Cancer After Female Breast Cancer by Age at Diagnosis Cite
  Mellemkjær L, Christensen J, Frederiksen K, Pukkala E, Weiderpass E, Bray F, et al. Risk of Primary Non–Breast Cancer After Female Breast Cancer by Age at Diagnosis. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2011; 20:1784-1792 10.1158/1055-9965.epi-11-0009
• Second primary breast, endometrial, and ovarian cancers in Black and White breast cancer survivors over a 35-year time span: effect of age Cite
  Nsouli-Maktabi HH, Henson DE, Younes N, Young HA, Cleary SD. Second primary breast, endometrial, and ovarian cancers in Black and White breast cancer survivors over a 35-year time span: effect of age. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 129:963-969 10.1007/s10549-011-1560-9
• Reproductive Status at First Diagnosis Influences Risk of Radiation-Induced Second Primary Contralateral Breast Cancer in the WECARE Study Cite
  Brooks JD, Boice JD, Stovall M, Reiner AS, Bernstein L, John EM, et al. Reproductive Status at First Diagnosis Influences Risk of Radiation-Induced Second Primary Contralateral Breast Cancer in the WECARE Study. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2012; 84:917-924 10.1016/j.ijrobp.2012.01.047
• Abstract 3585: Second primary tumors after breast cancer: Results from the European Prospective Investigation into Cancer and Nutrition (EPIC) study Cite
  Ricceri F, Sacerdote C, Critelli R, Vineis P, Riboli E. Abstract 3585: Second primary tumors after breast cancer: Results from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Epidemiology. American Association for Cancer Research; 2012; 10.1158/1538-7445.am2012-3585
• The Evaluation of Contralateral Breast Lesions in Breast Cancer Patients Using Reduction Mammoplasty Cite
  Dogan L, Gulcelik Ma, Bulut M, Karaman N, Kiziltan G, Ozaslan C. The Evaluation of Contralateral Breast Lesions in Breast Cancer Patients Using Reduction Mammoplasty. Journal of Breast Cancer. Korean Breast Cancer Society; 2011; 14:219 10.4048/jbc.2011.14.3.219
• Improved Outcomes of Breast-Conserving Therapy for Patients With Ductal Carcinoma in Situ Cite
  Halasz LM, Sreedhara M, Chen Y, Bellon JR, Punglia RS, Wong JS, et al. Improved Outcomes of Breast-Conserving Therapy for Patients With Ductal Carcinoma in Situ. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2012; 82:e581-e586 10.1016/j.ijrobp.2011.08.015
• Excess body weight and second primary cancer risk after breast cancer: a systematic review and meta-analysis of prospective studies Cite
  Druesne-Pecollo N, Touvier M, Barrandon E, Chan DSM, Norat T, Zelek L, et al. Excess body weight and second primary cancer risk after breast cancer: a systematic review and meta-analysis of prospective studies. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 135:647-654 10.1007/s10549-012-2187-1
• Bisphosphonate Use After Estrogen Receptor-Positive Breast Cancer and Risk of Contralateral Breast Cancer Cite
  Monsees GM, Malone KE, Tang MC, Newcomb PA, Li CI. Bisphosphonate Use After Estrogen Receptor-Positive Breast Cancer and Risk of Contralateral Breast Cancer. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2011; 103:1752-1760 10.1093/jnci/djr399
• Lobular Breast Cancer: Same Survival and Local Control Compared with Ductal Cancer, but Should Both Be Treated the Same Way? Analysis of an Institutional Database over a 10-Year Period Cite
  Fortunato L, Mascaro A, Poccia I, Andrich R, Amini M, Costarelli L, et al. Lobular Breast Cancer: Same Survival and Local Control Compared with Ductal Cancer, but Should Both Be Treated the Same Way? Analysis of an Institutional Database over a 10-Year Period. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2011; 19:1107-1114 10.1245/s10434-011-1907-9
• Body mass index and risk of second primary breast cancer: The WECARE Study Cite
  Brooks JD, John EM, Mellemkjær L, Reiner AS, Malone KE, Lynch CF, et al. Body mass index and risk of second primary breast cancer: The WECARE Study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 131:571-580 10.1007/s10549-011-1743-4
• Patient and tumor characteristics associated with contralateral breast cancer in a nested population-based case-control study. Cite
  Junqueira MJ, Morrow M, Reiner AS, Malone K, Lynch C, Bernstein JL. Patient and tumor characteristics associated with contralateral breast cancer in a nested population-based case-control study.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:1014-1014 10.1200/jco.2011.29.15_suppl.1014
• Long-Term Benefits of 5 Years of Tamoxifen: 10-Year Follow-Up of a Large Randomized Trial in Women at Least 50 Years of Age With Early Breast Cancer Cite
  Hackshaw A, Roughton M, Forsyth S, Monson K, Reczko K, Sainsbury R, et al. Long-Term Benefits of 5 Years of Tamoxifen: 10-Year Follow-Up of a Large Randomized Trial in Women at Least 50 Years of Age With Early Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:1657-1663 10.1200/jco.2010.32.2933
• Inflammatory breast cancer: high risk of contralateral breast cancer compared to comparably staged non-inflammatory breast cancer Cite
  Schairer C, Brown LM, Mai PL. Inflammatory breast cancer: high risk of contralateral breast cancer compared to comparably staged non-inflammatory breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 129:117-124 10.1007/s10549-010-1324-y
• Concordance in histological and biological parameters between first and second primary breast cancers Cite
  Huo D, Melkonian S, Rathouz PJ, Khramtsov A, Olopade OI. Concordance in histological and biological parameters between first and second primary breast cancers. Cancer. Wiley; 2010; 117:907-915 10.1002/cncr.25587
• Effect of the introduction of preoperative MRI scans for lobular cancer in an individual breast unit Cite
  Cain H, Sinclair J, Martin A, Fasih T, Browell D, Clark K, et al. Effect of the introduction of preoperative MRI scans for lobular cancer in an individual breast unit. Breast Cancer Research. Springer Science and Business Media LLC; 2010; 12 10.1186/bcr2680
• Mammographic Density and Risk of Second Breast Cancer after Ductal Carcinoma In situ Cite
  Habel LA, Capra AM, Achacoso NS, Janga A, Acton L, Puligandla B, et al. Mammographic Density and Risk of Second Breast Cancer after Ductal Carcinoma In situ. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2010; 19:2488-2495 10.1158/1055-9965.epi-10-0769
• Risk of second breast cancer according to estrogen receptor status and family history Cite
  Bouchardy C, Benhamou S, Fioretta G, Verkooijen HM, Chappuis PO, Neyroud-Caspar I, et al. Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 127:233-241 10.1007/s10549-010-1137-z
• Relationship between diabetes and risk of second primary contralateral breast cancer Cite
  Li CI, Daling JR, Tang MC, Malone KE. Relationship between diabetes and risk of second primary contralateral breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 125:545-551 10.1007/s10549-010-1035-4
• Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence Cite
  Yerushalmi R, Kennecke H, Woods R, Olivotto IA, Speers C, Gelmon KA. Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2008; 117:365-370 10.1007/s10549-008-0265-1
• Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age Cite
  van der Kolk DM, de Bock GH, Leegte BK, Schaapveld M, Mourits MJE, de Vries J, et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 124:643-651 10.1007/s10549-010-0805-3
• Population-Based Study of Contralateral Prophylactic Mastectomy and Survival Outcomes of Breast Cancer Patients Cite
  Bedrosian I, Hu C, Chang GJ. Population-Based Study of Contralateral Prophylactic Mastectomy and Survival Outcomes of Breast Cancer Patients. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2010; 102:401-409 10.1093/jnci/djq018
• Indications for Sentinel Lymph Node Biopsy in the Setting of Prophylactic Mastectomy Cite
  Laronga C, Lee MC, McGuire KP, Meade T, Carter WB, Hoover S, et al. Indications for Sentinel Lymph Node Biopsy in the Setting of Prophylactic Mastectomy. Journal of the American College of Surgeons. Elsevier BV; 2009; 209:746-752 10.1016/j.jamcollsurg.2009.08.010
• Second Primary Breast Cancer Occurrence According to Hormone Receptor Status Cite
  Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA. Second Primary Breast Cancer Occurrence According to Hormone Receptor Status. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2009; 101:1058-1065 10.1093/jnci/djp181
• Relationship Between Potentially Modifiable Lifestyle Factors and Risk of Second Primary Contralateral Breast Cancer Among Women Diagnosed With Estrogen Receptor–Positive Invasive Breast Cancer Cite
  Li CI, Daling JR, Porter PL, Tang MC, Malone KE. Relationship Between Potentially Modifiable Lifestyle Factors and Risk of Second Primary Contralateral Breast Cancer Among Women Diagnosed With Estrogen Receptor–Positive Invasive Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2009; 27:5312-5318 10.1200/jco.2009.23.1597
• Alcohol Intake and Cigarette Smoking and Risk of a Contralateral Breast Cancer: The Women's Environmental Cancer and Radiation Epidemiology Study Cite
  Knight JA, Bernstein L, Largent J, Capanu M, Begg CB, Mellemkjaer L, et al. Alcohol Intake and Cigarette Smoking and Risk of a Contralateral Breast Cancer: The Women's Environmental Cancer and Radiation Epidemiology Study. American Journal of Epidemiology. Oxford University Press (OUP); 2009; 169:962-968 10.1093/aje/kwn422